It's been a mediocre week for Genpact Limited (NYSE:G) shareholders, with the stock dropping 15% to US$42.46 in the week since its latest quarterly results. The result was positive overall - although revenues of US$1.2b were in line with what the analysts predicted, Genpact surprised by delivering a statutory profit of US$0.73 per share, modestly greater than expected. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Genpact after the latest results.

We've discovered 1 warning sign about Genpact. View them for free.NYSE:G Earnings and Revenue Growth May 10th 2025

Following last week's earnings report, Genpact's eleven analysts are forecasting 2025 revenues to be US$4.95b, approximately in line with the last 12 months. Statutory per share are forecast to be US$3.00, approximately in line with the last 12 months. In the lead-up to this report, the analysts had been modelling revenues of US$5.08b and earnings per share (EPS) of US$3.09 in 2025. The analysts are less bullish than they were before these results, given the reduced revenue forecasts and the minor downgrade to earnings per share expectations.

View our latest analysis for Genpact

The consensus price target fell 7.3% to US$52.03, with the weaker earnings outlook clearly leading valuation estimates. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. There are some variant perceptions on Genpact, with the most bullish analyst valuing it at US$56.00 and the most bearish at US$48.00 per share. Even so, with a relatively close grouping of estimates, it looks like the analysts are quite confident in their valuations, suggesting Genpact is an easy business to forecast or the the analysts are all using similar assumptions.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Genpact's past performance and to peers in the same industry. It's pretty clear that there is an expectation that Genpact's revenue growth will slow down substantially, with revenues to the end of 2025 expected to display 2.7% growth on an annualised basis. This is compared to a historical growth rate of 5.9% over the past five years. By way of comparison, the other companies in this industry with analyst coverage are forecast to grow their revenue at 6.9% per year. Factoring in the forecast slowdown in growth, it seems obvious that Genpact is also expected to grow slower than other industry participants.

Story Continues

The Bottom Line

The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for Genpact. On the negative side, they also downgraded their revenue estimates, and forecasts imply they will perform worse than the wider industry. Furthermore, the analysts also cut their price targets, suggesting that the latest news has led to greater pessimism about the intrinsic value of the business.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. At Simply Wall St, we have a full range of analyst estimates for Genpact going out to 2027, and you can see them free on our platform here..

That said, it's still necessary to consider the ever-present spectre of investment risk.  We've identified 1 warning sign  with Genpact , and understanding it should be part of your investment process.

Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

View Comments